# Post-Marketing Safety Study Following Long-Term Prophylactic OptivateTreatment in Subjects With Severe Haemophilia A

> **NCT01811875** · PHASE4 · TERMINATED · sponsor: **Bio Products Laboratory** · enrollment: 7 (actual)

## Conditions studied

- Haemophilia A

## Interventions

- **BIOLOGICAL:** Optivate 500IU

## Key facts

- **NCT ID:** NCT01811875
- **Lead sponsor:** Bio Products Laboratory
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-11-21
- **Primary completion:** 2017-08-31
- **Final completion:** 2017-08-31
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Study no longer required as Optivate German license expired in Sep-2017.
- **Last updated:** 2021-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01811875

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01811875, "Post-Marketing Safety Study Following Long-Term Prophylactic OptivateTreatment in Subjects With Severe Haemophilia A". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01811875. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*